Articles

CBA Members

Propriété
intellectuelle

Section du droit de la propriĂ©tĂ© intellectuelle de l’ABC

Les articles de la Section du droit de la propriĂ©tĂ© intellectuelle de l’ABC sont publiĂ©s par la Section du droit de la propriĂ©tĂ© intellectuelle. Les membres qui souhaitent proposer des articles sont invitĂ©s Ă  les envoyer Ă  la section Ă  : droitproprieteintellectuelleABC@cba.org.

AujourdÊŒhui
AujourdÊŒhui

Case summary: Federal Court awards declaratory and injunctive relief and $25,000 in punitive damages in trademark infringement action

  • 14 mai 2021
  • Jenny Thistle

Canadian Standards Association (“CSA”) sought declaratory and injunctive relief and an award of damages against Pharma Plastic Industries Inc., alleging Pharma Plastic manufactured, distributed, offered for sale and sold in Canada pharmaceutical vials and caps bearing the CSA’s registered trademarks without permission or license.

Propriété intellectuelle

Case summary: Federal Court confirms the applicable standard of review when new evidence is filed on appeal from a decision of the Registrar of Trademarks

  • 14 mai 2021
  • Jenny Thistle

BrandStorm, Inc. appealed, under section 56 of the Trademarks Act, a decision of the Trademarks Opposition Board made on behalf of the Registrar of Trademarks, rejecting BrandStorm’s opposition to an application by Naturally Splendid Enterprises Ltd. for registration of the trademark NATERA in association with a broad range of food, beverage and nutritional products.

Propriété intellectuelle

Case Summary: Allergan Inc v Sandoz Canada Inc.

  • 14 mai 2021
  • Mohit Sethi

This decision is a cost award arising from a patent infringement action pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations between Allergan Inc (“Allergan”) and Sandoz Canada Inc (“Sandoz”). The underlying action related to Allergan’s exclusive license of the 2,507,002 patent (“‘002 patent”) owned by Kissei Pharmaceutical Co. Ltd. (“Kissei”).

Propriété intellectuelle

Case Summary: The determination of appropriate disbursements cannot be sacrificed on the altar of simplicity

  • 13 mai 2021
  • David Schnittker

Apotex Inc. (“Apotex”) appealed a judgment of the Federal Court (2018 FC 1106) awarding Shire LLC (“Shire”) $1M in costs, and $600,000 in disbursements following its success at trial on a patent infringement action under the Patented Medicines (Notice of Compliance) (“PM(NOC)”) Regulations. Apotex was successful in part on its appeal.

Propriété intellectuelle

Case summary: Federal Court partially grants request for default judgment

  • 13 mai 2021
  • Hung Nguyen

On August 4, 2020, in TFI Foods Ltd v Every Green International Inc., 2020 FC 808, the Federal Court (the “Court”) issued an order enjoining Every Green International Inc. (“Every Green”) from offering for sale, selling, and/or labelling products bearing the trademark I-MEI Design with labels identifying Every Green as the exclusive distributor of I-MEI Foods Co, Ltd. Every Green did not comply with this order and took no further steps in its defense of the action.

Propriété intellectuelle

Case Summary: Federal Court of Appeal reviews motion for extension of time

  • 12 mai 2021
  • Hung Nguyen

Spectrum opposed Schneider’s application to register WISER. The Registrar allowed, in part, Spectrum’s opposition. Under the Trademarks Act, Spectrum and Schneider each had two months from the date of the Registrar’s decision to file an appeal.

Propriété intellectuelle

Case summary: Federal Court finds patent for method to delay onset of MS invalid for obviousness and upholds validity of second patent claiming a dose to alleviate MS symptoms

  • 12 mai 2021
  • Kelly McClellan

In two patent infringement actions under subsection 6(1) of the PM (NOC) Regulations, [the Regulations], the Federal Court found the claims of the ‘437 Patent invalid for obviousness and dismissed the action for infringement against the ‘802 Patent, finding the patent valid, not obvious, and useful (29, 32).

Propriété intellectuelle